ArticleScientific reports2026
Light-triggered drug release via fiber optic heater-integrated with thermoresponsive microgels for locoregional cancer therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer treatment faces significant challenges due to the nonspecific delivery of chemotherapeutic drugs, resulting in systemic toxicity and limited efficacy. Targeted, localized drug delivery systems offer a transformative approach to overcome these limitations by improving therapeutic precision and minimizing side effects. Here, we propose the development of a novel light-to-heat triggered drug delivery (FO-LTDR) platform by integrating a fiber optic heater (FOH) with doxorubicin-loaded thermoresponsive microgels (DOX@MGs) for the locoregional treatment of cancer. The DOX@MGs, developed using a N-isopropylmethacrylamide-maleic acid formulation, exhibit superior drug loading capacity and controlled release properties, that ensure stability under physiological conditions and selective activation under external thermal stimuli. The FOH is engineered with a core-offset fusion splice and a gold-coated region that enables efficient conversion of optical to thermal energy. The thermal response of the platform is monitored in real time via an integrated fiber Bragg grating. The heat generated by the fiber results in a "squeezing effect" of the microgels covalently bound to its surface, releasing pure doxorubicin in a controlled manner strictly at the site of interest. The FO-LTDR platform demonstrated precise, on-demand drug delivery in 2D/3D MCF7 models, providing a versatile and controllable approach that could transform future strategies for localized chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.